Procaps Group Past Earnings Performance
Past criteria checks 1/6
Procaps Group has been growing earnings at an average annual rate of 53.6%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been growing at an average rate of 6.5% per year. Procaps Group's return on equity is 135.8%, and it has net margins of 12.6%.
Key information
53.6%
Earnings growth rate
57.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 6.5% |
| Return on equity | 135.8% |
| Net Margin | 12.6% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
These 4 Measures Indicate That Procaps Group (NASDAQ:PROC) Is Using Debt Extensively
Mar 28
Is Procaps Group S.A. (NASDAQ:PROC) Worth US$3.7 Based On Its Intrinsic Value?
Feb 02Calculating The Intrinsic Value Of Procaps Group S.A. (NASDAQ:PROC)
Feb 01Procaps Group reports Q2 results
Aug 30Calculating The Fair Value Of Procaps Group, S.A. (NASDAQ:PROC)
Jan 10Revenue & Expenses BreakdownBeta
How Procaps Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 414 | 52 | 179 | 0 |
| 30 Jun 23 | 406 | 67 | 174 | 0 |
| 31 Mar 23 | 408 | 33 | 183 | 0 |
| 31 Dec 22 | 410 | 43 | 185 | 0 |
| 30 Sep 22 | 435 | 60 | 175 | 0 |
| 30 Jun 22 | 431 | -73 | 168 | 0 |
| 31 Mar 22 | 418 | -67 | 156 | 0 |
| 31 Dec 21 | 410 | -101 | 151 | 0 |
| 30 Sep 21 | 401 | -119 | 157 | 0 |
| 30 Jun 21 | 374 | -9 | 147 | 0 |
| 31 Mar 21 | 342 | -18 | 137 | 0 |
| 31 Dec 20 | 331 | -10 | 128 | 0 |
| 01 Jan 20 | 325 | -17 | 145 | 0 |
Quality Earnings: PROC has a large one-off gain of $40.5M impacting its last 12 months of financial results to 30th September, 2023.
Growing Profit Margin: PROC's current net profit margins (12.6%) are lower than last year (13.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PROC has become profitable over the past 5 years, growing earnings by 53.6% per year.
Accelerating Growth: PROC's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: PROC had negative earnings growth (-13.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-6.8%).
Return on Equity
High ROE: Whilst PROC's Return on Equity (135.77%) is outstanding, this metric is skewed due to their high level of debt.